Format
Sort by

Send to

Choose Destination

Search results

Items: 7

1.

Tenofovir DF/emtricitabine and efavirenz combination therapy for HIV infection in patients treated for tuberculosis: the ANRS 129 BKVIR trial.

Lortholary O, Roussillon C, Boucherie C, Padoin C, Chaix ML, Breton G, Rami A, Veziris N, Patey O, Caumes E, May T, Molina JM, Robert J, Tod M, Fagard C, Chêne G; ANRS 129 BKVIR Trial Group.

J Antimicrob Chemother. 2016 Mar;71(3):783-93. doi: 10.1093/jac/dkv384. Epub 2015 Dec 17.

PMID:
26679250
2.

Impact of gag genetic determinants on virological outcome to boosted lopinavir-containing regimen in HIV-2-infected patients.

Larrouy L, Vivot A, Charpentier C, Bénard A, Visseaux B, Damond F, Matheron S, Chene G, Brun-Vezinet F, Descamps D; ANRS CO5 HIV-2 Cohort.

AIDS. 2013 Jan 2;27(1):69-80. doi: 10.1097/QAD.0b013e32835a10d8.

PMID:
23018441
3.

Dynamics of gag-pol minority viral populations in naive HIV-1-infected patients failing protease inhibitor regimen.

Larrouy L, Charpentier C, Landman R, Capitant C, Chazallon C, Yeni P, Peytavin G, Damond F, Brun-Vezinet F, Descamps D; ANRS 127 study group.

AIDS. 2011 Nov 13;25(17):2143-8. doi: 10.1097/QAD.0b013e32834cabb9.

PMID:
21904187
4.

Efficacy and safety of unboosted atazanavir in combination with lamivudine and didanosine in naive HIV type 1 patients in Senegal.

Landman R, Diallo MB, Gueye NF, Kane CT, Mboup S, Fall MB, Ndiaye B, Peytavin G, Bennai Y, Benalycherif A, Girard PM, Sow PS.

AIDS Res Hum Retroviruses. 2010 May;26(5):519-25. doi: 10.1089/aid.2009.0123.

PMID:
20455760
5.

Gag mutations can impact virological response to dual-boosted protease inhibitor combinations in antiretroviral-naïve HIV-infected patients.

Larrouy L, Chazallon C, Landman R, Capitant C, Peytavin G, Collin G, Charpentier C, Storto A, Pialoux G, Katlama C, Girard PM, Yeni P, Aboulker JP, Brun-Vezinet F, Descamps D; ANRS 127 Study Group.

Antimicrob Agents Chemother. 2010 Jul;54(7):2910-9. doi: 10.1128/AAC.00194-10. Epub 2010 May 3.

6.

Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study.

Landman R, Capitant C, Descamps D, Chazallon C, Peytavin G, Katlama C, Pialoux G, Bentata M, Brun-Vézinet F, Aboulker JP, Yéni P; ANRS 127 Study Group.

J Antimicrob Chemother. 2009 Jul;64(1):118-25. doi: 10.1093/jac/dkp146. Epub 2009 May 6.

7.

Viral efficacy maintained and safety parameters improved with a reduced dose of stavudine: a pilot study.

Ait-Mohand H, Bonmarchand M, Guiguet M, Slama L, Marguet F, Behin A, Amellal B, Bennai Y, Peytavin G, Calvez V, Pialoux G, Murphy R, Katlama C.

HIV Med. 2008 Oct;9(9):738-46. doi: 10.1111/j.1468-1293.2008.00616.x. Epub 2008 Jul 21.

Items per page

Supplemental Content

Loading ...
Write to the Help Desk